drugset / Trial / NCT07802821
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 in combination with QL2107 versus Tislelizumab plus platinum and etoposide as first-line treatment in participants with extensive-stage small cell lung cancer.
Timeline
- Start
- 2026-10-15
- Primary completion
- 2029-03-15
- Completion
- 2030-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Cisplatin | Other / unclassified | — | Intravenous |
| Comparator | Etoposide | Small molecule | — | Intravenous |
| Subject | QL2107 | Unknown | — | Intravenous |
| Subject | QLC5508 | Other / unclassified | — | Intravenous |
| Comparator | Tislelizumab | Monoclonal antibody | — | Intravenous |